These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11402259)

  • 1. Ziprasidone (Geodon) for schizophrenia.
    Med Lett Drugs Ther; 2001 Jun; 43(1106):51-2. PubMed ID: 11402259
    [No Abstract]   [Full Text] [Related]  

  • 2. Focus on ziprasidone.
    Green B
    Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
    Kane JM
    J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
    [No Abstract]   [Full Text] [Related]  

  • 4. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM; Shayegan DK
    J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintaining symptom control: review of ziprasidone long-term efficacy data.
    Schooler NR
    J Clin Psychiatry; 2003; 64 Suppl 19():26-32. PubMed ID: 14728087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three cases of schizophrenia showing improvement after switching to blonanserin.
    Kurotaki N; Nobata H; Nonaka S; Nishihara K; Ozawa H
    Psychiatry Clin Neurosci; 2011 Jun; 65(4):396-7. PubMed ID: 21682816
    [No Abstract]   [Full Text] [Related]  

  • 7. Tolerability of ziprasidone: an expanding perspective.
    Daniel DG
    J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziprasidone: a new atypical antipsychotic.
    Keck PE; McElroy SL; Arnold LM
    Expert Opin Pharmacother; 2001 Jun; 2(6):1033-42. PubMed ID: 11585006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziprasidone: a novel psychotropic with unique properties.
    Ballas C; Yang C; O'Reardon J; Ballas P; Baldassano C
    Expert Rev Neurother; 2004 Mar; 4(2):179-86. PubMed ID: 15853558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From clinical research to clinical practice: a 4-year review of ziprasidone.
    Nemeroff CB; Lieberman JA; Weiden PJ; Harvey PD; Newcomer JW; Schatzberg AF; Kilts CD; Daniel DG
    CNS Spectr; 2005 Nov; 10(11 Suppl 17):1-20. PubMed ID: 16381088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ziprasidone and cognition: the evolving story.
    Harvey PD
    J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ziprasidone and dementia].
    Aakhus E
    Tidsskr Nor Laegeforen; 2004 Aug; 124(16):2155-6; author reply 2155-6. PubMed ID: 15334150
    [No Abstract]   [Full Text] [Related]  

  • 13. Strategies for successful clinical management of schizophrenia with ziprasidone.
    Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
    Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic.
    Daniel DG; Copeland LF
    Expert Opin Investig Drugs; 2000 Apr; 9(4):819-28. PubMed ID: 11060712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ziprasidone treatment of delirium.
    Leso L; Schwartz TL
    Psychosomatics; 2002; 43(1):61-2. PubMed ID: 11927760
    [No Abstract]   [Full Text] [Related]  

  • 16. Iloperidone for schizophrenia.
    Rado J; Janicak PG
    Expert Opin Pharmacother; 2010 Aug; 11(12):2087-93. PubMed ID: 20586713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ziprasidone. A new second-generation antipsychotic agent].
    Lublin HK
    Ugeskr Laeger; 2004 Mar; 166(14):1334-9. PubMed ID: 15101124
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.
    Zink M; Mase E; Dressing H
    Hum Psychopharmacol; 2004 Jun; 19(4):271-3. PubMed ID: 15181656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS).
    Bernardo M; Azanza JR; Rubio-Terrés C; Rejas J
    Actas Esp Psiquiatr; 2007; 35(4):259-62. PubMed ID: 17592789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lack of effect of ziprasidone on platelet serotonin concentration in schizophrenic patients.
    Sagud M; Nikolac M; Mihaljevic-Peles A; Nedic G; Vuksan Cusa B; Mustapic M; Jakovljevic M; Muck-Seler D; Pivac N
    Psychopharmacology (Berl); 2012 Feb; 219(4):1179-81. PubMed ID: 21989808
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.